Bruton tyrosine kinase inhibitors have improved persistent lymphocytic leukemia outcomes and supply a chemotherapy-free possibility . The BTK inhibitor ibrutinib, alone or with a CD20 antibody, demonstrated higher efficacy versus chemoimmunotherapy in treatment-naïve CLL [2–4]….